vs
Apellis Pharmaceuticals, Inc.（APLS）与福泰制药（VERX）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是福泰制药的1.0倍（$199.9M vs $194.7M），福泰制药净利率更高（-3.6% vs -29.5%，领先25.9%），福泰制药同比增速更快（9.1% vs -5.9%），过去两年福泰制药的营收复合增速更高（11.4% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
福泰制药是一家总部位于美国马萨诸塞州波士顿的生物制药企业，是全球首批明确采用理性药物设计策略而非组合化学方法的生物技术公司之一。除波士顿总部外，公司还在加利福尼亚州圣迭戈、英国牛津郡米尔顿公园设有三处研发中心，专注于创新药物的研发与商业化。
APLS vs VERX — 直观对比
营收规模更大
APLS
是对方的1.0倍
$194.7M
营收增速更快
VERX
高出15.0%
-5.9%
净利率更高
VERX
高出25.9%
-29.5%
两年增速更快
VERX
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $194.7M |
| 净利润 | $-59.0M | $-7.0M |
| 毛利率 | — | 64.8% |
| 营业利润率 | -25.6% | -1.3% |
| 净利率 | -29.5% | -3.6% |
| 营收同比 | -5.9% | 9.1% |
| 净利润同比 | -62.2% | 89.7% |
| 每股收益（稀释后） | $-0.40 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSVERX
| Q4 25 | $199.9M | $194.7M | ||
| Q3 25 | $458.6M | $192.1M | ||
| Q2 25 | $178.5M | $184.6M | ||
| Q1 25 | $166.8M | $177.1M | ||
| Q4 24 | $212.5M | $178.5M | ||
| Q3 24 | $196.8M | $170.4M | ||
| Q2 24 | $199.7M | $161.1M | ||
| Q1 24 | $172.3M | $156.8M |
净利润APLSVERX
| Q4 25 | $-59.0M | $-7.0M | ||
| Q3 25 | $215.7M | $4.0M | ||
| Q2 25 | $-42.2M | $-961.0K | ||
| Q1 25 | $-92.2M | $11.1M | ||
| Q4 24 | $-36.4M | $-67.8M | ||
| Q3 24 | $-57.4M | $7.2M | ||
| Q2 24 | $-37.7M | $5.2M | ||
| Q1 24 | $-66.4M | $2.7M |
毛利率APLSVERX
| Q4 25 | — | 64.8% | ||
| Q3 25 | — | 63.1% | ||
| Q2 25 | — | 65.7% | ||
| Q1 25 | — | 63.8% | ||
| Q4 24 | — | 65.6% | ||
| Q3 24 | — | 64.8% | ||
| Q2 24 | — | 63.7% | ||
| Q1 24 | — | 61.1% |
营业利润率APLSVERX
| Q4 25 | -25.6% | -1.3% | ||
| Q3 25 | 48.7% | 2.2% | ||
| Q2 25 | -18.6% | -2.1% | ||
| Q1 25 | -50.0% | 2.5% | ||
| Q4 24 | -12.3% | -7.3% | ||
| Q3 24 | -24.0% | 2.9% | ||
| Q2 24 | -14.7% | 4.7% | ||
| Q1 24 | -36.0% | -1.0% |
净利率APLSVERX
| Q4 25 | -29.5% | -3.6% | ||
| Q3 25 | 47.0% | 2.1% | ||
| Q2 25 | -23.6% | -0.5% | ||
| Q1 25 | -55.3% | 6.3% | ||
| Q4 24 | -17.1% | -38.0% | ||
| Q3 24 | -29.2% | 4.2% | ||
| Q2 24 | -18.9% | 3.2% | ||
| Q1 24 | -38.5% | 1.7% |
每股收益（稀释后）APLSVERX
| Q4 25 | $-0.40 | — | ||
| Q3 25 | $1.67 | — | ||
| Q2 25 | $-0.33 | — | ||
| Q1 25 | $-0.74 | — | ||
| Q4 24 | $-0.30 | — | ||
| Q3 24 | $-0.46 | — | ||
| Q2 24 | $-0.30 | — | ||
| Q1 24 | $-0.54 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $314.0M |
| 总债务越低越好 | — | $337.5M |
| 股东权益账面价值 | $370.1M | $258.9M |
| 总资产 | $1.1B | $1.3B |
| 负债/权益比越低杠杆越低 | — | 1.30× |
8季度趋势，按日历期对齐
现金及短期投资APLSVERX
| Q4 25 | $466.2M | $314.0M | ||
| Q3 25 | $479.2M | $313.5M | ||
| Q2 25 | $370.0M | $284.4M | ||
| Q1 25 | $358.4M | $270.4M | ||
| Q4 24 | $411.3M | $296.1M | ||
| Q3 24 | $396.9M | $279.0M | ||
| Q2 24 | $360.1M | $325.5M | ||
| Q1 24 | $325.9M | $56.1M |
总债务APLSVERX
| Q4 25 | — | $337.5M | ||
| Q3 25 | — | $336.9M | ||
| Q2 25 | — | $336.3M | ||
| Q1 25 | — | $335.8M | ||
| Q4 24 | — | $335.2M | ||
| Q3 24 | — | $334.7M | ||
| Q2 24 | — | $334.1M | ||
| Q1 24 | $93.1M | $46.0M |
股东权益APLSVERX
| Q4 25 | $370.1M | $258.9M | ||
| Q3 25 | $401.2M | $264.5M | ||
| Q2 25 | $156.3M | $248.0M | ||
| Q1 25 | $164.2M | $200.5M | ||
| Q4 24 | $228.5M | $179.4M | ||
| Q3 24 | $237.1M | $259.0M | ||
| Q2 24 | $264.3M | $233.1M | ||
| Q1 24 | $266.7M | $250.1M |
总资产APLSVERX
| Q4 25 | $1.1B | $1.3B | ||
| Q3 25 | $1.1B | $1.2B | ||
| Q2 25 | $821.4M | $1.2B | ||
| Q1 25 | $807.3M | $1.2B | ||
| Q4 24 | $885.1M | $1.2B | ||
| Q3 24 | $901.9M | $1.2B | ||
| Q2 24 | $904.5M | $1.0B | ||
| Q1 24 | $831.9M | $755.8M |
负债/权益比APLSVERX
| Q4 25 | — | 1.30× | ||
| Q3 25 | — | 1.27× | ||
| Q2 25 | — | 1.36× | ||
| Q1 25 | — | 1.67× | ||
| Q4 24 | — | 1.87× | ||
| Q3 24 | — | 1.29× | ||
| Q2 24 | — | 1.43× | ||
| Q1 24 | 0.35× | 0.18× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $42.3M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSVERX
| Q4 25 | $-14.2M | $42.3M | ||
| Q3 25 | $108.5M | $62.5M | ||
| Q2 25 | $4.4M | $46.0M | ||
| Q1 25 | $-53.4M | $14.8M | ||
| Q4 24 | $19.4M | $41.1M | ||
| Q3 24 | $34.1M | $41.4M | ||
| Q2 24 | $-8.3M | $57.7M | ||
| Q1 24 | $-133.0M | $24.6M |
自由现金流APLSVERX
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | — | $-24.3M | ||
| Q2 24 | $-8.4M | — | ||
| Q1 24 | $-133.3M | $10.1M |
自由现金流率APLSVERX
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | — | -14.2% | ||
| Q2 24 | -4.2% | — | ||
| Q1 24 | -77.3% | 6.5% |
资本支出强度APLSVERX
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | 38.5% | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.2% | 9.2% |
现金转化率APLSVERX
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 15.44× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.33× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 5.73× | ||
| Q2 24 | — | 11.18× | ||
| Q1 24 | — | 9.15× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
VERX
| Cloud Subscriptions | $94.6M | 49% |
| Software Licenses | $71.6M | 37% |
| Service Other | $28.5M | 15% |
